News & Updates

Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.

Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.

Pregnancies in women who have survived cervical cancer or leukaemia should be considered high-risk due to the potential for multiple severe obstetric complications, as reported in a study.